AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36739285
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitors (AI)
Trial: 32070246
Drug: Levothyroxine (LT4)
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (LT4) supplementation (8 μg/kg birthweight/day as a single daily dose)
Trial: 35411074
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin therapy (10 mg and 25 mg, orally administered, 7 days apart)
Trial: 35411074
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin therapy (2 × 25 mg, orally administered, 3 weeks apart, plus 6 weeks of daily placebo)
Trial: 35411074
Drug: Escitalopram (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (2 × 1 mg, orally administered, 3 weeks apart, plus 6 weeks of daily escitalopram 10–20 mg)
Trial: 34933978
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (monthly home visits)
Trial: 34618479
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behavioral therapy (CA‐CBT)
Trial: 34849429
Drug: Paracetamol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1000 mg in 150 ml normal saline)
Trial: 34849429
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg in 150 ml normal saline)
Trial: 32524424
Drug: Elevated efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elevated efavirenz concentration (≥ 4.0 mg/L)
Trial: 33299890
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg per day)
Trial: 32250057
Drug: Remimazolam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam (single intravenous injection)
Trial: 33032771
Drug: Intravenous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous golimumab 2 mg/kg
Trial: 32978200
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg or 150 mg two times per day
Trial: 32978200
Drug: Warfarin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin with international normalised ratio 2-3
Trial: 35552386
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no LED treatment)
Trial: 33408282
Drug: 2-hourly feeding
RxNorm normalized name: BAGS,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hourly feeding schedule
Trial: 33408282
Drug: 3-hourly feeding
RxNorm normalized name: SYRINGE,FEEDING ENFIT 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hourly feeding schedule
Trial: 32041644
Drug: High-dose EAA/protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose EAA/protein composition (12.6g protein, 3.2g EAA per serving)
Trial: 32041644
Drug: Low-dose EAA/protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose EAA/protein composition (6.3g protein, 1.6g EAA per serving)
Trial: 34436509
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg/d) + standard of care (SOC: 40 mg dihydroartemisinin + 320 mg piperaquine/d)
Trial: 34436509
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC: 40 mg dihydroartemisinin + 320 mg piperaquine/d)
Trial: 34875022
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous iron
Trial: 34875022
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous iron
Trial: 33829920
Drug: Daily sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sustained physical activity (PA)
Trial: 32235773
Drug: Milk Protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk Protein Isolate (MPI) - 0.7 g protein/kg/d
Trial: 32235773
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) - 0.7 g carbohydrate/kg/d
Trial: 33945886
Drug: Self-affirmation followed
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-affirmation followed by gain-framed health messages daily
Trial: 33945886
Drug: Daily loss-framed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily loss-framed health messages only
Trial: 34799275
Drug: Individualized follitropin
RxNorm normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Individualized follitropin delta dosing
Trial: 33144049
Drug: PPAA (polaprezinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPAA (polaprezinc in polyacrylic acid solution)
Trial: 35157493
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of BNT162b2 vaccine
Trial: 34112656
Drug: Usual escalation
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual escalation (5 mg every 4 weeks)
Trial: 34112656
Drug: Fast escalation
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast escalation (5 mg every 2 weeks)
Trial: 32925765
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (health education and Tiotropium bromide)
Trial: 33225995
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly self-collected oral swabs (OS) regardless of symptoms
Trial: 33225995
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly self-collected oral-nares swab (O-NS) regardless of symptoms
Trial: 33225995
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly nurse collected nasopharyngeal swab (NPS) regardless of symptoms
Trial: 33225995
Drug: Active daily
RxNorm normalized name: HOMOSALATE 3 mL in 100 mL / OCTINOXATE 8 mL in 100 mL / OXYBENZONE 2 mL in 100 mL TOPICAL LIQUID [GLAMTOX ACTIVE DAILY MOISTURIZING SUNSCREEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active daily surveillance of symptoms and testing only in symptomatic participants (comparator group)
Trial: 34667294
Drug: CVN058 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVN058 150 mg
Trial: 34052211
Drug: RDN using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery)
Trial: 33135737
Drug: LEAP238-47 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEAP238-47 infusion in healthy human individuals (n=10)
Trial: 36354718
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (100 mg adjunct testosterone, seven weekly injections)
Trial: 32586361
Drug: Bilateral TQL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral TQL block with 30 ml ropivacaine 0.375% each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (TQL group, n=75)
Trial: 32586361
Drug: Bilateral TQL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral TQL block with 30 ml saline each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (placebo group, n=75)
Trial: 33583740
Drug: Amoxicillin administered
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin administered 24 hours pre-operatively
Trial: 33583740
Drug: Amoxicillin administered
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin administered 48 hours pre-operatively
Trial: 33583740
Drug: Amoxicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before surgery)
Trial: 36772948
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication treatment
Trial: 33757937
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter with concurrent oxytocin administration
Trial: 36097565
Drug: Integrated rehabilitation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated rehabilitation (combination of TCM and Western conventional rehabilitation methods including acupuncture, repeated transcranial magnetic stimulation, traditional Chinese herbal medicine, and standard care)
Trial: 34321316
Drug: SCO-267 (GPR40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCO-267 (GPR40 full agonist)
Trial: 34120773
Drug: Dasatinib 140
RxNorm normalized name: dasatinib 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 140 mg once daily
Trial: 34602349
Drug: methotrexate, vinblastine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles)
Trial: 34602349
Drug: cisplatin (mandatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin (mandatory minimum total dose of 270 mg/m2)
Trial: 34602349
Drug: cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin-based chemotherapy (at least 4 cycles)
Trial: 34602349
Drug: cisplatin (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin (full doses given in 1866 cycles, 88%)
Trial: 32723264
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg sublingual melatonin the evening before and 1 hour before surgery
Trial: 35686812
Drug: Percutaneous ablation
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous ablation therapy (AT)
Trial: 32198638
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel (Group B)
Trial: 35963369
Drug: Ivarmacitinib 8
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivarmacitinib 8 mg QD
Trial: 35963369
Drug: Ivarmacitinib 4
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivarmacitinib 4 mg BID
Trial: 35963369
Drug: Ivarmacitinib 4
RxNorm normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivarmacitinib 4 mg QD
Trial: 38214552
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA
Trial: 35920250
Drug: Low-dose magnesium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose magnesium sulfate solution (MSS)
Trial: 32070395
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administered at a loading dose of 1 g, followed by 1 g every 8 hours for a maximum of 24 hours, in addition to standard care.
Trial: 35859928
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum IL6_0 (≥3.67 pg/mL)
Trial: 35859928
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum TNFα_0 (≥14.8 pg/mL)
Trial: 32722250
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Probiotic (Saccharomyces cerevisiae CNCM I-3856)
Trial: 32722250
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Probiotic (Saccharomyces cerevisiae CNCM I-3856)
Trial: 34335740
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapy)
Trial: 32444035
Drug: Barberry extract
RxNorm normalized name: barberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barberry extract (500 mg, 6 capsules daily for 3 months)
Trial: 35578351
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (complex intervention to encourage deprescribing antidepressants)
Trial: 34541630
Drug: Hormonal oral
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal oral contraceptive
Trial: 32661756
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) agonist for 4 months preoperatively (group G)
Trial: 32661756
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) agonist
Trial: 32661756
Drug: Dienogest (DNG)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest (DNG) and Gonadotropin-releasing hormone (GnRH) agonist
Trial: 35644672
Drug: Double dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dosage of 23-valent pneumococcal polysaccharide vaccine (PPV23) in WLPs
Trial: 35644672
Drug: Normal dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dosage of 23-valent pneumococcal polysaccharide vaccine (PPV23) in WLPs
Trial: 35644672
Drug: Double dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dosage of pneumococcal vaccines in KTRs
Trial: 35644672
Drug: Normal dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dosage of pneumococcal vaccines in KTRs
Trial: 35644672
Drug: Double dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dosage of pneumococcal vaccines in WLPs
Trial: 34184576
Drug: Early lactate-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early lactate-guided treatment
Trial: 34516655
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 μg) and Vitamin E (400 units) for 3 months
Trial: 35656824
Drug: Clopidogrel‐aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel‐aspirin
Trial: 35869572
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy for 12 months
Trial: 33484896
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (HIIT) thrice-weekly for 12 weeks
Trial: 33484896
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) daily doses of 12.5 mg for 12 weeks
Trial: 35241434
Drug: L-PF Dyspnoea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PF Dyspnoea score
Trial: 35241434
Drug: L-PF Cough
RxNorm normalized name: Pediaclear Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PF Cough score
Trial: 32151287
Drug: Wild blueberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild blueberry (WBB) supplementation (253 mg anthocyanins daily for 4 weeks)
Trial: 35988194
Drug: Clarithromycin capsules
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin capsules (Control)
Trial: 32918135
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg FA/day
Trial: 32918135
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g creatine
Trial: 32434399
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at a dose of 150 mg at bedtime
Trial: 33252489
Drug: Intervention (psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (psychosocial counseling, systems navigation, and antiretroviral treatment)
Trial: 34627684
Drug: Conventional infertility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional infertility treatment
Trial: 33526728
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet treatment with aspirin 100‐160 mg once daily and clopidogrel 75 mg once daily for three months (Group A)
Trial: 33526728
Drug: Aspirin 100‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100‐160 mg once daily for three months (Group B)
Trial: 33526728
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C) treated according to appropriate treatment guidelines
Trial: 34814819
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (DPA and EPA)
Trial: 34464231
Drug: Optimal response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Optimal response adaptive design for treatment allocation
Trial: 35082514
Drug: Ticagrelor treatment
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor treatment
Trial: 37488448
Drug: Cetuximab treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab treatment
Trial: 34474433
Drug: CV̇O2 (42.49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV̇O2 (42.49 ± 3.22 ml·kg−1·min−1)
Trial: 34474433
Drug: CV̇O2slow (38.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV̇O2slow (38.26 ± 2.43 ml·kg−1·min−1)
Trial: 32967775
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE) 4 g daily (2 g BID with food)
Trial: 32967775
Drug: Placebo (paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (paraffin oil 2 g BID with food)
Trial: 35849020
Drug: FAMily‐Oriented Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAMily‐Oriented Support (FAMOS) family therapy program, includes seven home-based psychotherapeutic sessions
Trial: 33356580
Drug: Hydrogen-rich water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich water (HRW); six 30-min ankle baths throughout the first 24 hours post-injury, administered every 4 hours.
Trial: 39631042
Drug: Budesonide oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide oral suspension (BOS) 2.0 mg twice daily
Trial: 32783280
Drug: Hybrid method
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid method (using loose seeds in combination with stranded seeds)
Trial: 36322627
Drug: Immunosuppressive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive drugs
Trial: 34470913
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.3 g/kg body mass) with warm-up
Trial: 35418868
Drug: Drugs for
RxNorm normalized name: DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for GERD
Trial: 33214093
Drug: IVIg (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (400 mg/kg, IV, daily for three days)
Trial: 34527921
Drug: Orofacial exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orofacial exercise program twice a day for one month in addition to oral hygiene care advices (Group 1)
Trial: 34527921
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene care advices for the first month followed by orofacial exercise program for the next month (Group 2)
Trial: 36027955
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanic acid administration
Trial: 36027955
Drug: Timing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing of antibiotic administration
Trial: 36047047
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation of hydroxychloroquine (200 mg tablet)
Trial: 36047047
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation of hydroxychloroquine (200 mg tablet)
Trial: 37450351
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy (ET)